Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?Zacks Investment Research • 08/08/23
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023PRNewsWire • 07/26/23
Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/26/23
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaPRNewsWire • 07/21/23
Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a BetZacks Investment Research • 07/19/23
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersPRNewsWire • 06/02/23
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023PRNewsWire • 05/31/23
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare ConferencePRNewsWire • 05/30/23
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/11/23
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial GuidancePRNewsWire • 05/10/23
Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 05/02/23
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023PRNewsWire • 04/27/23
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023PRNewsWire • 04/26/23
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/26/23
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual MeetingPRNewsWire • 04/19/23